{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:22:11Z","timestamp":1770880931852,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dengue is the most prevalent arboviral infection causing an estimated 50\u201360 million cases of febrile illness globally per year, exacting considerable disease burden. Few instruments exist to assess the patient illness experience, with most based on healthcare provider assessment, lacking standardization in timepoints and symptom assessment. This study aimed to evaluate the content validity of the novel \u2018Dengue Virus Daily Diary (DENV-DD)\u2019, designed to measure symptom intensity and disease burden within outpatient infant to adult populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Dengue Illness Index Report Card was used as a foundation to create the DENV-DD, consisting of patient- and observer-reported outcome (PRO\/ObsRO) instruments. In two South American dengue-endemic communities, qualitative combined concept elicitation and cognitive debriefing interviews were conducted among individuals and caregivers of children with symptomatic laboratory-confirmed dengue. Interviews were conducted across two rounds allowing DENV-DD modifications. A small-scale quantitative assessment of the DENV-DD was also conducted with data from an independent Dengue Human Infection Model (DHIM) to generate early evidence of feasibility of DENV-DD completion, instrument performance and insight into the sign\/symptom trajectory over the course of illness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty-eight participants were interviewed (20 adults, 20 older children\/adolescents with their caregivers, 8 caregivers of younger children). A wide spectrum of signs\/symptoms lasting 3\u201315\u00a0days were reported with fever, headache, body ache\/pain, loss of appetite, and body weakness each reported by\u2009&gt;\u200970% participants. DENV-DD instructions, items and response scales were understood, and items were considered relevant across ages. DHIM data supported feasibility of DENV-DD completion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Findings demonstrate content validity of the DENV-DD (PRO\/ObsRO instruments) in dengue-endemic populations. Psychometric and cultural validity studies are ongoing to support use of the DENV-DD in clinical studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00624-5","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:34:46Z","timestamp":1692783286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Measuring dengue illness intensity: Development and content validity of the dengue virus daily diary (DENV-DD)"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3645-746X","authenticated-orcid":false,"given":"Amy M.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd L.","family":"Saretsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Panter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane R.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verity","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Kendal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelyn","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawna R.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Gater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn B.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie A.","family":"Paz-Soldan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Ware","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Klick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan A.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"issue":"9","key":"624_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.vaccine.2016.10.070","volume":"35","author":"World Health Organisation","year":"2017","unstructured":"World Health Organisation (2017) Dengue vaccine: WHO position paper, July 2016\u2013recommendations. Vaccine 35(9):1200\u20131201","journal-title":"Vaccine"},{"key":"624_CR2","unstructured":"World Health Organisation (2022) Dengue and severe dengue"},{"issue":"36","key":"624_CR3","first-page":"457","volume":"93","author":"World Health Organisation","year":"2018","unstructured":"World Health Organisation (2018) Dengue vaccine: WHO position paper, September 2018. Wkly Epidemiol Rec 93(36):457\u2013476","journal-title":"Wkly Epidemiol Rec"},{"issue":"528","key":"624_CR4","doi-asserted-by":"publisher","first-page":"eaax4144","DOI":"10.1126\/scitranslmed.aax4144","volume":"12","author":"L Cattarino","year":"2020","unstructured":"Cattarino L et al (2020) Mapping global variation in dengue transmission intensity. Sci Transl Med 12(528):eaax4144","journal-title":"Sci Transl Med"},{"issue":"7","key":"624_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/tmi.12498","volume":"20","author":"NT Toan","year":"2015","unstructured":"Toan NT et al (2015) Dengue epidemiology in selected endemic countries: factors influencing expansion factors as estimates of underreporting. Trop Med Int Health 20(7):840\u2013863","journal-title":"Trop Med Int Health"},{"key":"624_CR6","unstructured":"Institute for Health Metrics and Evaluation. Dengue \u2014 Level 3 cause. 2019 [cited 25th November 2022 25th November 2022]. https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/dengue-level-3-cause"},{"issue":"1","key":"624_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","volume":"1","author":"AB Sabin","year":"1952","unstructured":"Sabin AB (1952) Research on dengue during World War II. Am J Trop Med Hyg 1(1):30\u201350","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"624_CR8","first-page":"178","volume":"10","author":"E Prompetchara","year":"2019","unstructured":"Prompetchara E et al (2019) Dengue vaccine: global development update. Asian Pac J Allergy Immunol 10(3):178\u2013185","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"suppl_2","key":"624_CR9","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1093\/infdis\/jiu061","volume":"209","author":"MC Cassetti","year":"2014","unstructured":"Cassetti MC, Thomas SJ (2014) Dengue human infection model: introduction. J Infect Dis 209(suppl_2):S37\u2013S39","journal-title":"J Infect Dis"},{"key":"624_CR10","unstructured":"World Health Organisation (2009) Dengue: guidelines for diagnosis, treatment, prevention and control"},{"issue":"21","key":"624_CR11","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal S et al (2019) Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 381(21):2009\u20132019","journal-title":"N Engl J Med"},{"issue":"9951","key":"624_CR12","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR et al (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384(9951):1358\u20131365","journal-title":"Lancet"},{"issue":"10","key":"624_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006593","volume":"12","author":"SJ Thomas","year":"2018","unstructured":"Thomas SJ et al (2018) Dengue illness index\u2014a tool to characterize the subjective dengue illness experience. PLoS Negl Trop Dis 12(10):e0006593","journal-title":"PLoS Negl Trop Dis"},{"key":"624_CR14","unstructured":"US Food & Drug Administration (2018) Patient-focused drug development guidance: select, develop or modify fit-for-purpose clinical outcome assessments"},{"key":"624_CR15","unstructured":"US Food & Drug Administration (2018) Patient-focused drug development guidance: methods to identify what is important to patients"},{"key":"624_CR16","unstructured":"US Food & Drug Administration (2018) Patient-focused drug development guidance: collecting comprehensive and representative input. guidance for industry"},{"issue":"4","key":"624_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","volume":"16","author":"LS Matza","year":"2013","unstructured":"Matza LS et al (2013) Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health 16(4):461\u2013479","journal-title":"Value Health"},{"issue":"1","key":"624_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41687-018-0035-8","volume":"2","author":"C Acquadro","year":"2018","unstructured":"Acquadro C et al (2018) Emerging good practices for translatability assessment (TA) of patient-reported outcome (PRO) measures. J Patient-Reported Outcomes 2(1):8","journal-title":"J Patient-Reported Outcomes"},{"key":"624_CR19","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/j.jval.2019.04.966","volume":"22","author":"T Saretsky","year":"2019","unstructured":"Saretsky T et al (2019) PIN96 development of patient-reported outcome (PRO) and observer-reported outcome (ObsRO) measures for assessment of symptom intensity in dengue illness. Value Health 22:S210","journal-title":"Value Health"},{"key":"624_CR20","first-page":"100277","volume":"12","author":"MM Hasan","year":"2022","unstructured":"Hasan MM et al (2022) Concurrent epidemics of dengue and COVID-19 in Peru: which way forward? Lancet Reg Health Am 12:100277","journal-title":"Lancet Reg Health Am"},{"issue":"5","key":"624_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.4269\/ajtmh.17-0762","volume":"98","author":"AM Stewart-Ibarra","year":"2018","unstructured":"Stewart-Ibarra AM et al (2018) The burden of dengue fever and chikungunya in southern coastal Ecuador: epidemiology, clinical presentation, and phylogenetics from the first two years of a prospective study. Am J Trop Med Hyg 98(5):1444\u20131459","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"624_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009257","volume":"15","author":"CA Lippi","year":"2021","unstructured":"Lippi CA et al (2021) Exploring the utility of social-ecological and entomological risk factors for dengue infection as surveillance indicators in the dengue hyper-endemic city of Machala, Ecuador. PLoS Negl Trop Dis 15(3):e0009257","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"624_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1073\/pnas.1213349110","volume":"110","author":"ST Stoddard","year":"2013","unstructured":"Stoddard ST et al (2013) House-to-house human movement drives dengue virus transmission. Proc Natl Acad Sci U S A 110(3):994\u2013999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"624_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000670","volume":"4","author":"AC Morrison","year":"2010","unstructured":"Morrison AC et al (2010) Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis 4(5):e670","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"624_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM et al (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839\u2013842","journal-title":"Value Health"},{"issue":"1","key":"624_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L (2006) How many interviews are enough? An experiment with data saturation and variability. Field Methods 18(1):59\u201382","journal-title":"Field Methods"},{"issue":"4","key":"624_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1080\/2159676X.2017.1331501","volume":"9","author":"DW Eccles","year":"2017","unstructured":"Eccles DW, Arsal G (2017) The think aloud method: what is it and how do I use it? Qual Res Sport Exerc Health 9(4):514\u2013531","journal-title":"Qual Res Sport Exerc Health"},{"key":"624_CR28","unstructured":"GmbH, A.t.S.S.D (2017) ATLAS.ti 8 Windows. [8.0]"},{"key":"624_CR29","unstructured":"Marks M et al (2022) Dengue virus daily diary (DENV-DD)\u2014a new patient-reported outcome (PRO) tool measuring dengue symptom intensity: Findings from a DEN-3 human challenge study. American Society for Tropical Medicine and Hygiene"},{"key":"624_CR30","doi-asserted-by":"crossref","unstructured":"Waickman AT et al (2022) Virologic, clinical, and immunological characteristics of a dengue virus 3 human challenge model. medRxiv","DOI":"10.1101\/2022.10.24.22281454"},{"issue":"7","key":"624_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008477","volume":"14","author":"WH Elson","year":"2020","unstructured":"Elson WH et al (2020) Measuring health related quality of life for dengue patients in Iquitos, Peru. PLoS Negl Trop Dis 14(7):e0008477","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"624_CR32","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3201\/eid2609.191472","volume":"26","author":"WH Elson","year":"2020","unstructured":"Elson WH et al (2020) Heterogeneity of dengue illness in community-based prospective study, Iquitos, Peru. Emerg Infect Dis 26(9):2077","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"624_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1128\/CMR.11.3.480","volume":"11","author":"DJ Gubler","year":"1998","unstructured":"Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11(3):480\u2013496","journal-title":"Clin Microbiol Rev"},{"key":"624_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fimmu.2014.00183","volume":"5","author":"TP Endy","year":"2014","unstructured":"Endy TP (2014) Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Front Immunol 5:183","journal-title":"Front Immunol"},{"key":"624_CR35","unstructured":"US Food & Drug Administration (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims"},{"issue":"s1","key":"624_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1179\/2046904712Z.00000000046","volume":"32","author":"R Tapia-Conyer","year":"2012","unstructured":"Tapia-Conyer R, Betancourt-Cravioto M, M\u00e9ndez-Galv\u00e1n J (2012) Dengue: an escalating public health problem in Latin America. Paediatr Int Child Health 32(s1):14\u201317","journal-title":"Paediatr Int Child Health"},{"key":"624_CR37","unstructured":"Torres R JR, Torres V CG (2002) Dengue in Latin America-a unique situation"},{"issue":"1","key":"624_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4269\/ajtmh.2010.09-0346","volume":"82","author":"JL San Mart\u00edn","year":"2010","unstructured":"San Mart\u00edn JL et al (2010) The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 82(1):128\u2013135","journal-title":"Am J Trop Med Hyg"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00624-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00624-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00624-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T03:02:41Z","timestamp":1700535761000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00624-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00624-5","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved and overseen by Naval Medical Research Unit No. 6 Institutional Review Board (IRB) in Peru (NAMRU6.2014.0028) and by central SUNY Upstate IRB (417710) and Luis Vernaza Hospital (HLV-CEISH-2020-005) in Ecuador, in compliance with all applicable federal regulations governing the protection of human subjects. All participants provided written informed consent and\/or assent (for children aged 8\u00a0years and above only) prior to study-related activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dissemination of findings including via publication was included in the consent form signed by participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Amy M. Jones, Charlotte Panter, Frances White, Verity Smith, Helen Kendal and Adam Gater are employees of Adelphi Values Ltd, a health outcome agency, who were paid by the study sponsor (Merck Sharpe & Dohme) to conduct the research described in this manuscript and write this manuscript. Jane R. Wells was an employee of Adelphi Values Ltd at the time of research and is now employed by Sanofi. Todd L. Saretsky, Kevin Russell, Madelyn Ruggieri, Shawna R, Calhoun and Justin O\u2019Hagan are employees of Merck Sharpe & Dohme, the study sponsor. Morgan A. Marks was an employee of Merck Sharpe & Dohme at the time of research and is now employed by Moderna Inc. Kathryn B. Anderson, Lisa Ware, Michelle Klick and Stephen Thomas are employees of State University of New York and were involved in the running of the Dengue Human Infection Model where the DENV-DD was implemented. Kathryn B. Anderson was also involved in the recruitment of dengue participants from the Ecuador site. Valarie A. Paz-Soldan is an employee of Tulane School of Public Health and Tropical Medicine and Amy C. Morrison is an employee of the University of California, Davis and were both involved in the recruitment of dengue participants from the Peru site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}